Aaron P Yamniuk

20130095109, Apr 18, 2013

Oct 12, 2012

13/650493

Bristol-Myers Squibb Company - Princeton NJ, US
Domantis Limited - Brentford, GB
Laura PRICE - Langhorne PA, US
Robert P. REHFUSS - North Wales PA, US
Suzanne J. SUCHARD - Wilmington DE, US
Anish SURI - Yardley PA, US
James William BRYSON - Langhorne PA, US
Aaron YAMNIUK - Lawrenceville NJ, US
Steven GRANT - Cambridge, GB
Olga IGNATOVICH - Cambridge, GB
Philip DREW - Cambridge, GB

DOMANTIS LIMITED - Brentford
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

C07K 16/28
A61K 39/395
A61K 45/06
C07K 16/46

4241391, 5303879, 5303873, 536 2353, 4353201, 435331

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

20220324989, Oct 13, 2022

Mar 15, 2022

17/694890

- Princeton NJ, US
- South San Francisco CA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Shannon L. OKADA - Seattle WA, US
Brenda L. STEVENS - Seattle WA, US
James William WEST - South San Francisco CA, US

Bristol-Myers Squibb Company - Princeton NJ
CytomX Therapeutics, Inc. - South San Francisco CA

C07K 16/28
C12N 15/63

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

20220175921, Jun 9, 2022

Nov 19, 2021

17/531061

- Princeton NJ, US
Nils LONBERG - Woodside CA, US
Alan J. KORMAN - Piedmont CA, US
Mark J. SELBY - San Francisco CA, US
Mohan SRINIVASAN - Cupertino CA, US
Karla A. HENNING - Milpitas CA, US
Michelle Minhua HAN - Piedmont CA, US
Guodong CHEN - East Brunswick NJ, US
Richard Y. HUANG - Bridgewater NJ, US
Indrani CHAKRABORTY - Fremont CA, US
Haichun HUANG - Fremont CA, US
Susan Chien-Szu WONG - Fremont CA, US
Huiming LI - Lexington MA, US
Bryan C. BARNHART - Vancouver, CA
Aaron P. YAMNIUK - Lawrenceville NJ, US
Ming LEI - Princeton NJ, US
Liang SCHWEIZER - Lawrenceville NJ, US
Sandra V. HATCHER - Hillsborough NJ, US
Arvind RAJPAL - San Francisco CA, US

A61K 39/395
C07K 16/28
G01N 33/574
G01N 33/68

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

20230051701, Feb 16, 2023

May 5, 2022

17/737403

- Princeton NJ, US
Alan J. Korman - Piedmont CA, US
Bryan C. Barnhart - Vancouver CA, US
Aaron P. Yamniuk - Lawrenceville NJ, US
Mohan Srinivasan - Cupertino CA, US
Karla A. Henning - Milpltas CA, US
Ming Lei - Princeton NJ, US
Emanuela Sega - Cupertino CA, US
Angela Goodenough - Morrisville PA, US
Guodong Chen - East Brunswick NJ, US
John S. Sack - Lawrenceville NJ, US
Richard Huang - Bridgewater NJ, US
Martin J. Corbett - Mount Holly NJ, US
Liang Schweizer - Cambridge MA, US
Sandra V. Hatcher - Hillsborough NJ, US
Haichun Huang - Fremont CA, US
Pingping Zhang - Cupertino CA, US

C07K 16/40
C07K 16/28
C07K 16/30
A61K 39/395
G01N 33/573
A61K 47/68
A61K 45/06
G01N 33/574

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

20210403561, Dec 30, 2021

Sep 10, 2021

17/472302

- Princeton NJ, US
Michael L. GOSSELIN - Boston MA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Derek A. HOLMES - Lawrenceville NJ, US
Guodong CHEN - East Brunswick NJ, US
Priyanka Apurva MADIA - Franklin Park NJ, US
Richard Yu-Cheng HUANG - Bridgewater NJ, US
Stephen Michael CARL - Howell NJ, US

C07K 16/28
A61K 47/68
C12N 15/85
A61P 29/00

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

20210054091, Feb 25, 2021

Nov 6, 2020

17/091375

- Princeton NJ, US
Brigitte DEVAUX - Palo Alto CA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Shannon L. OKADA - Seattle WA, US
Brenda L. STEVENS - Seattle WA, US

C07K 16/28
A61P 31/12
A61P 35/02
A61P 35/04
A61P 35/00

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

20200339700, Oct 29, 2020

Dec 27, 2018

16/958563

- Princeton NJ, US
- South San Francisco CA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Shannon L. OKADA - Seattle WA, US
Brenda L. STEVENS - Seattle WA, US
James William WEST - South San Francisco CA, US

Bristol-Myers Squibb Company - Princeton NJ
CytomX Therapeutics, Inc. - South San Francisco CA

C07K 16/28
C12N 15/63

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

20200299400, Sep 24, 2020

May 24, 2018

16/612867

- Princeton NJ, US
Alan J. KORMAN - Piedmont CA, US
Mark J. SELBY - San Francisco CA, US
Bryan C. BARNHART - San Francisco CA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Mohan SRINIVASAN - Cupertino CA, US
Karla A. HENNING - Milpitas CA, US
Michelle Minhua HAN - Piedmont CA, US
Ming LEI - Princeton NJ, US
Liang SCHWEIZER - Shanghai PR, CI
Sandra V. HATCHER - Hillsborough NJ, US
Arvind RAJPAL - San Francisco CA, US

BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

C07K 16/28

Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.